搜尋結果
2024年8月1日 · Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023. Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties.
Diversity is a source of innovation and an important approach to realize our corporate concept. Eisai has been promoting the creation of a corporate culture in which people with diverse values can play an active role regardless of nationality, gender, age, or other factors.
Lecanemab is an investigational humanized monoclonal antibody for Alzheimer’s disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic.
LEQEMBI is the world’s first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
January 7, 2023. Eisai Co., Ltd. EISAI’S APPROACH TO U.S. PRICING FOR LEQEMBITM (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER’S DISEASE, SETS FORTH OUR CONCEPT OF “SOCIETAL VALUE OF MEDICINE” IN RELATION TO “PRICE OF MEDICINE” MAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY .
LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. Hong Kong is the fifth approval, following approvals in the U.S., Japan, China, and South Korea. LEQEMBI’s approval in Hong Kong is based on the large global Phase 3 Clarity AD study.
LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI has also been approved in the U.S., Japan, China, South Korea and Hong Kong, and is being marketed in the U.S. Japan and China.
